Clarivate PLC (NYSE:CLVT – Get Free Report) insider Bar Veinstein sold 254,558 shares of the stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $2.13, for a total value of $542,208.54. Following the completion of the sale, the insider owned 1,008,458 shares in the company, valued at approximately $2,148,015.54. The trade was a 20.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Clarivate Trading Down 2.0%
Shares of NYSE:CLVT traded down $0.04 on Friday, hitting $2.01. 5,696,820 shares of the company’s stock were exchanged, compared to its average volume of 5,910,554. Clarivate PLC has a 12 month low of $1.42 and a 12 month high of $3.87. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -3.30 and a beta of 1.38. The business’s 50 day simple moving average is $1.87 and its two-hundred day simple moving average is $2.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 0.88 and a quick ratio of 0.88.
Clarivate (NYSE:CLVT – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. The firm had revenue of $481.60 million for the quarter, compared to analysts’ expectations of $566.77 million. Clarivate had a negative net margin of 17.02% and a positive return on equity of 9.84%. The business’s revenue for the quarter was down 22.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.18 earnings per share. Analysts anticipate that Clarivate PLC will post 0.67 EPS for the current fiscal year.
Analyst Ratings Changes
CLVT has been the topic of a number of research analyst reports. William Blair downgraded shares of Clarivate to a “market perform” rating in a research note on Thursday, October 15th. The Goldman Sachs Group decreased their price target on shares of Clarivate from $2.60 to $2.30 and set a “neutral” rating for the company in a research note on Thursday, November 5th. Stifel Nicolaus lowered their price target on Clarivate from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Citigroup dropped their price objective on Clarivate from $2.80 to $2.50 and set a “neutral” rating on the stock in a research note on Thursday, July 30th. Finally, Morgan Stanley began coverage on Clarivate in a report on Friday, October 30th. They set an “underweight” rating and a $1.50 price objective on the stock. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $2.65.
Get Our Latest Stock Report on Clarivate
Institutional Investors Weigh In On Clarivate
Several large investors have recently modified their holdings of CLVT. American Century Companies Inc. lifted its position in shares of Clarivate by 30.2% in the 3rd quarter. American Century Companies Inc. now owns 18,566,836 shares of the company’s stock worth $31,007,000 after purchasing an additional 4,301,119 shares during the period. Aquatic Capital Management LLC purchased a new position in Clarivate during the third quarter valued at approximately $104,000. Ares Systematic Credit Ltd bought a new position in Clarivate in the third quarter worth approximately $583,000. Goldman Sachs Group Inc. raised its stake in Clarivate by 379.0% in the third quarter. Goldman Sachs Group Inc. now owns 4,625,784 shares of the company’s stock worth $7,725,000 after buying an additional 3,659,973 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in Clarivate during the third quarter worth $111,000. Institutional investors own 85.72% of the company’s stock.
About Clarivate
Clarivate provides information, analytics and workflow tools to customers in academia and government, life sciences and healthcare, and intellectual property. Its services help organizations find and analyze research, assess scientific and commercial developments, and manage patents, trademarks and other intellectual property. Its products include Web of Science and ProQuest research resources, Cortellis life sciences intelligence, and intellectual property databases and services such as Derwent.
Read More
- Five stocks we like better than Clarivate
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.
